Sentences with word «toceranib»

PDGFR - α, PDGFR - β, VEGFR - 2 and CD117 expression in canine mammary tumours and evaluation of the in vitro effects of toceranib phosphate in neoplastic mammary cell lines

We have recently completed a study evaluating toceranib in combination with doxorubicin as treatment for cancer in dogs.

Multi-center, placebo - controlled, double - blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.

MONTREAL --(BUSINESS WIRE)-- Pfizer Animal Health today announced that the U.S. Food and Drug Administration (FDA) has approved the first canine cancer therapy in the U.S.» PALLADIATM (toceranib phosphate)» which was developed by Pfizer to treat mast cell tumors in dogs.

The U.S. Food and Drug Administration announced the approval of Palladia (toceranib phosphate) on the first day of the conference; this is the first drug developed specifically for the treatment of cancer in dogs.

One of the newest forms of drug treatment is Palladia (toceranib phosphate).

Previous studies have shown that the drug Palladia (toceranib) can reverse resistance to doxorubicin (a commonly used anticancer drug).